Corporate Headquarters

11555 Sorrento Valley Road, Suite 100, San Diego, CA 92121
Tel: (858) 224-1000

Find Us On

Modeling NAFLD and TGF beta-induced fibrosis in ExVive™ human liver tissue

Jeff Irelan, Director Scientific Applications, Organovo | Alice Chen, Director Tissue Applications, Organovo
Presented live on June 8, 2017


Publication Summary:

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder with an estimated prevalence of over 25% worldwide and is projected to become the leading indication for liver transplant by 2025.  Despite decades of research focused on NAFLD, an effective treatment has yet to be approved.  This is due in part to the reliance on cell culture and animal models that present challenges in translation due to limited functional longevity and species differences, respectively.  ExVive™ Human Liver Tissue, a clinically-translatable in vitro model, is ideal for studying the effects of drugs on liver disease progression, regression, and the mechanisms involved.  Here we present results showing a nutrient overload induction of liver disease and TGFβ-induced fibrosis in ExVive™ Human Liver Tissue.  A variety of disease-relevant phenotypes including steatosis, inflammation, and fibrosis can be demonstrated in the model.
loading your video...